WEBULL
WebtradeDownload

How FDA Filing Acceptance Will Impact Bayer (XTRA:BAYN) Investors

Simply Wall St · 2d ago
  • Bayer reported that the FDA previously accepted its supplemental New Drug Application for KERENDIA in adults with chronic kidney disease without diabetes, backed by Phase III FIND-CKD data showing a statistically significant slowing of kidney function decline and kidney cardiovascular risk versus placebo on top of standard of care.
  • The FIND-CKD results suggest Bayer is attempting to extend KERENDIA beyond diabetic kidney disease into a broader chronic kidney disease population, which could influence how investors view the durability and scale of its cardiovascular renal medicine franchise.
  • We will now examine how Bayer's investment narrative could be affected by the FDA review of KERENDIA's non diabetic CKD label.

Scan how Bayer's KERENDIA story compares with other potential compounders in kidney and cardiovascular care by reviewing the 129 healthcare AI stocks that are already trying to reshape treatment pathways.

Bayer Investment Narrative Recap

To own Bayer, you need to believe management can turn a pressured balance sheet and unprofitable group earnings into healthier cash generation while its pharma pipeline replaces older products. The FDA review of Kerendia in non diabetic CKD is part of that story but does not change the immediate swing factors, which remain cash flow, litigation timing and execution in Crop Science.

Over the next year or so, the key potential upside catalyst is follow through on the 2024 to 2029 efficiency plan and working capital release, along with visible progress on litigation outflows. The biggest risk is that cash remains tight because payouts, restructuring and large capital expenditures such as the Ohio plant continue to absorb funds faster than new therapies such as Kerendia can contribute.

The Kerendia sNDA comes on top of a broader refresh in Bayer pharmaceuticals that already includes label expansions in chronic kidney disease and heart failure, together with launches such as Lynkuet and HYRNUO. This cluster of products gives the pharma unit more shots on goal while Crop Science restructures and Consumer Health continues in the background.

For investors, the connection is the mix shift that analysts have been watching. The more Bayer can rely on drugs like Kerendia and future pipeline assets, the more room it may have to absorb restructuring noise, high litigation funding and the long payback on new manufacturing projects without disrupting efforts to achieve sustained positive free cash flow.

What The Current Analyst Framework Implies For Bayer

Analysts sketch a Bayer outline that hinges on steady expansion in the top line and a sharp swing in profitability. The current forecasts point to revenue growth of 2.6% a year and assume earnings move from a loss of €1.7 billion today to €3.7 billion by 2029, which is an earnings increase of €5.4 billion over that period. On those numbers, the consensus view lines up with revenues of €49.0 billion and earnings of €3.7 billion in 2029.

Uncover why Bayer's fair value indicates a 32% potential upside to its current price that may not last much longer.

XTRA:BAYN 1-Year Stock Price Chart
XTRA:BAYN 1-Year Stock Price Chart

Exploring Other Perspectives

The bearish analysts focus on one issue you cannot ignore as you consider Bayer today: the drag from litigation cash outflows. They were already assuming only 1.4% annual revenue growth to about €47.3b and earnings of €3.5b by 2029. That is more cautious than consensus, and both views may change as the Kerendia sNDA story develops.

Explore 6 other Bayer fair value estimates, including one that suggests it could be worth just €46.00.

Decide For Yourself

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

  • A great starting point for your Bayer research is our analysis highlighting 4 key rewards that could impact your investment decision.
  • See our latest analysis for Bayer. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Bayer's overall financial health at a glance.

Looking For More Investment Ideas Beyond Bayer?

Once you have a view on Bayer, it can help to set that thesis against what else the market is offering across different styles and risk levels.